Clinical use of a growth hormone receptor antagonist in the treatment of acromegaly

By Drake W.M.   Parkinson C.   Besser G.M.   Trainer P.J.  

Trends in Endocrinology and Metabolism, Vol. 12, Iss. 9, 2001-11 ,pp. : 408-413

Elsevier

Access to resources Recommend Favorite

Clinical Use of Pegvisomant for the Treatment of Acromegaly

By Drake William M.  

Treatments in Endocrinology, Vol. 2, Iss. 6, 2003-01 ,pp. : 369-374

Adis International

Access to resources Recommend Favorite

The exon 3 polymorphism of the growth hormone receptor is a severity-related factor for osteoporosis

By Marques Felipe   Lins Túlio   Lima Ricardo   Fonseca Rômulo   França Nanci   Oliveira Ricardo   Oliveira Cardoso Maria   Pereira Rinaldo   Pogue Robert  

Endocrine, Vol. 45, Iss. 3, 2014-04 ,pp. : 487-496

Springer Publishing Company

Access to resources Recommend Favorite

Growth hormone measurements in the diagnosis and monitoring of acromegaly

By Sata Akira   Ho Ken  

Pituitary, Vol. 10, Iss. 2, 2007-06 ,pp. : 165-172

Springer Publishing Company

Access to resources Recommend Favorite

Absence of immunostaining for growth hormone in a subset of patients with acromegaly

By Schroeder Jason   Spiotta Alejandro   Fleseriu Maria   Prayson Richard   Hamrahian Amir   Weil Robert  

Pituitary, Vol. 17, Iss. 2, 2014-04 ,pp. : 103-108

Springer Publishing Company

Access to resources Recommend Favorite